TRYPF   $0.055  1.85% Market Closed

Tryp Therapeutics Inc
Last Events:

2023-08-09 Trend pattern changed from канал to расширяющийся канал.

2023-08-09 Signal in MACD changed from bearish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and it crossed the zero line from the bottom. These factors mean that there is probably a growing trend. Last signal: up-crossing the middle level.

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-09 Trend changed from down and flat to linear down.

2023-08-05 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-07-29 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: main and signal line crossing.

2023-07-29 Trend Power changed from medium strength to .


Current temperature: 0.56
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None Sell None
stoch None Sell None
ma20 None None ActivelyBuy
ma50 None None None
ma100 None Sell None
Candlestick PatternMarch 10, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CA89854F1062
ceo Mr. Jason Carroll
Website https://www.tryptherapeutics.com
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.